| 2.31 -0.04 (-1.7%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.11 | 1-year : | 3.64 |
| Resists | First : | 2.66 | Second : | 3.11 |
| Pivot price | 2.44  |
|||
| Supports | First : | 2.21 | Second : | 1.94 |
| MAs | MA(5) : | 2.39 |
MA(20) : | 2.41 |
| MA(100) : | 4.09 |
MA(250) : | 4.32 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 27.1 |
D(3) : | 37.8 |
| RSI | RSI(14): 44.2 |
|||
| 52-week | High : | 12.36 | Low : | 1.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LPCN ] has closed below the lower bollinger band by 2.5%. Bollinger Bands are 88.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 55 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.36 - 2.38 | 2.38 - 2.39 |
| Low: | 2.27 - 2.29 | 2.29 - 2.31 |
| Close: | 2.28 - 2.32 | 2.32 - 2.34 |
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
Tue, 07 Jul 2026
Lipocine Inc. (LPCN) Holds Near Support After Modest Gain, Resistance in Focus - Analyst Upgrade Stocks - DonanımHaber
Tue, 30 Jun 2026
Lipocine (LPCN) CEO Mahesh Patel receives 52,781 stock options grant - Stock Titan
Fri, 26 Jun 2026
Price to book forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Thu, 04 Jun 2026
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 - Yahoo Finance
Tue, 19 May 2026
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting - PR Newswire
Thu, 02 Apr 2026
Oral ‘roid void in PPD? Lipocine MINI bike may have wheels - BioWorld News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 6.91e+006 (%) |
| Held by Institutions | 4.5 (%) |
| Shares Short | 90 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.207e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 224 % |
| Return on Equity (ttm) | -33.1 % |
| Qtrly Rev. Growth | 2e+006 % |
| Gross Profit (p.s.) | 61.81 |
| Sales Per Share | -123.66 |
| EBITDA (p.s.) | 4.54545e+006 |
| Qtrly Earnings Growth | -2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.33 |
| Dividend | 0 |
| Forward Dividend | 141720 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|